China Pet Nutraceuticals - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The china pet nutraceuticals market was USD 420.0 million in 2025, projected to reach USD 470.0 million in 2026 and USD 870.0 million by 2031, with a CAGR of 13.11% from 2026 to 2031. This report is Segmented by Sub Product (Milk Bioactives, Omega-3 Fatty Acids, Probiotics, Proteins and Peptides, Vitamins and Minerals, and Other Nutraceuticals), by Pets (Cats, Dogs, and Other Pets), and by Distribution Channel (Convenience Stores, Online Channel, Specialty Stores, and More). The Market Forecasts are Provided in Terms of Value (USD) and Volume (Metric Tons).

China Pet Nutraceuticals Market Trends and Insights

Premiumization of Pet Care and Humanization of Pets

The China pet nutraceuticals market is benefiting from a broader shift in how urban households care for companion animals, with spending patterns increasingly resembling those in family health and wellness categories. Average pet food prices on major Chinese e-commerce platforms increased, indicating that pet owners are willing to move beyond entry-level price bands and invest in higher-quality products. This trend is significant for the pet nutraceuticals market, as it demonstrates a growing acceptance of premium spending on pet nutrition and care. Cross-sector participation further highlights the market's potential, with companies such as Kweichow Moutai developing pet food from protein byproducts and dairy producers Mengniu and Yili introducing pet nutrition lines in China. This diversification suggests that the China pet nutraceuticals market is increasingly being regarded as a stable consumer category rather than a niche specialty. Additionally, the emphasis on formulation quality and documentation is becoming more critical, as premium buyers are more discerning, and the evolving MARA (China's Ministry of Agriculture and Rural Affairs) framework is anticipated to favor brands that can substantiate their product claims with robust evidence.

Rising Veterinary Recommendation of Preventive Nutrition

The shift from casual, owner-led supplement trials to more structured, veterinary-recommended use is anticipated to drive market growth. Royal Canin has supported this trend by investing in veterinary education and fostering relationships with breeding centers, thereby contributing to more consistent, repeat usage rather than impulse-driven purchases. In 2026, Royal Canin introduced therapeutic nutrition innovations aligned with vet-led care pathways, strengthening the link between clinical advice and nutrition-based management. Similarly, Purina Pro Plan’s AdvantEDGE line, launched in 2024, focuses on digestive and immune health, demonstrating how global suppliers are adapting products for easier integration into professional care settings. This development is significant for the China pet nutraceuticals market, as owner confidence increases when product selection is tied to a defined care routine rather than general wellness claims. Additionally, it benefits companies that can effectively combine product science, channel training, and compliance with regulatory requirements under China's licensed production rules for therapeutic pet supplements.

Limited Consumer Trust in Product Efficacy Claims

The China pet nutraceuticals market continues to face challenges related to consumer trust, as mandatory clinical evidence requirements for functional claims lag behind the expectations of a growing premium market segment. This discrepancy allows both well-supported and poorly substantiated products to appear similar on digital platforms, making it difficult for pet owners to assess product efficacy prior to purchase. The February 2026 class action settlement involving Nutramax Laboratories over alleged misrepresentation of the benefits of its Cosequin canine joint supplement highlights how global events can influence consumer skepticism in China, particularly among digitally savvy buyers. While the August 2025 MARA (China's Ministry of Agriculture and Rural Affairs) consultation on hygiene and labeling standards was a significant step, it did not fully address the credibility issues surrounding functional claims. Brands that commit to extended research efforts, such as H&H Group’s five-year development of the HHP003 probiotic strain, are better positioned to leverage this skepticism into a competitive advantage. However, the growth of the China pet nutraceuticals market is likely to remain slower than its potential if consumer confidence continues to rely more on brand reputation than on verified product efficacy.

Other drivers and restraints analyzed in the detailed report include:

• Growth of Digestive and Joint Health Formulations for Aging Pets
• Expansion of E-commerce Driven Repeat Purchases
• Price Sensitivity Outside Tier 1 and Tier 2 Cities

Segment Analysis

Probiotics accounted for 23% of revenue in 2025, making them the largest sub-product in the China pet nutraceuticals market. The market size for probiotics is projected to grow at a CAGR of 15.6% through 2031. This combination of significant market share and robust growth highlights that microbiome-focused products have transitioned from a niche segment to a key category within the China pet nutraceuticals industry. For instance, H&H Group’s Solid Gold brand invested five years in developing the HHP003 cat-derived probiotic strain, specifically designed for indoor cat metabolic management, which was launched commercially in April 2026. Such initiatives strengthen the market by tying category growth to research-driven differentiation rather than relying solely on generic wellness claims.

While probiotics dominate, other sub-products remain integral to the market, serving distinct roles within the category structure. Omega-3 fatty acids continue to hold a significant position in the China pet nutraceuticals market. DSM-Firmenich’s launch of microalgal oil in April 2026 marks a shift toward more stable, sustainable ingredient supply options. Vitamins and minerals, proteins and peptides, and milk bioactives serve as foundational nutrition platforms, though they are not the primary drivers of premium growth. Additionally, emerging categories such as postbiotics and novel bioactives are gaining traction. ADM’s PRIOME portfolio indicates that future growth in the China pet nutraceuticals market may stem from microbiome-linked innovations beyond traditional probiotics.The evolving sub-product mix reflects a market that is expanding in scientific sophistication while maintaining strong consumer demand for products associated with visible, everyday benefits. This balance between innovation and practicality underscores the dynamic nature of the China pet nutraceuticals industry.

Complete Report Scope:

• By Sub Product
  • Milk Bioactives
  • Omega-3 Fatty Acids
  • Probiotics
  • Proteins and Peptides
  • Vitamins and Minerals
  • Other Pet Nutraceuticals
• By Pets
  • Cats
  • Dogs
  • Other Pets
• By Distribution Channel
  • Convenience Stores
  • Online Channel
  • Specialty Stores
  • Supermarkets/Hypermarkets
  • Other Channels

List of Companies Covered in this Report:

• Mars, Incorporated
• Nestle S.A. (Purina)
• Colgate-Palmolive Company (Hill's Pet Nutrition Inc.)
• Zoetis Inc.
• Virbac
• Vetoquinol S.A.
• Boehringer Ingelheim International GmbH
• Beijing Yuanyue Pet Products Co., Ltd.
• DSM-Firmenich
• ADM
• H&H Group
• Nutramax Laboratories, Inc.
• PetHonesty
• GNC Holdings, LLC
• NOW Foods

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support